ScholarIQanswers from OpenAlex

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

PaperCitations, authors & open-access status

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States have?

ScholarIQcitation count

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States has 20 citations in the OpenAlex counts ScholarIQ stores.

When was Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States published?

ScholarIQyear

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States has 2012 year in the ScholarIQ index.

What is the open-access status of Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States?

ScholarIQoa status

Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States has bronze oa status in the ScholarIQ index.

What is the DOI of Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States?

ScholarIQdoi

The DOI for Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States is on the source record.

What is the PMID of Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States?

ScholarIQpmid

The PMID for Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States is on the source record.

What is the OpenAlex record for Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States?

ScholarIQopenalex

The OpenAlex for Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial